Cencora, Inc. (NYSE:COR) Shares Acquired by Twin Capital Management Inc.

Twin Capital Management Inc. increased its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 18.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 14,148 shares of the company's stock after acquiring an additional 2,162 shares during the quarter. Twin Capital Management Inc.'s holdings in Cencora were worth $3,179,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. JFS Wealth Advisors LLC boosted its holdings in shares of Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after purchasing an additional 46 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in Cencora in the 4th quarter worth about $30,000. Kentucky Trust Co purchased a new stake in Cencora in the 4th quarter valued at about $33,000. Householder Group Estate & Retirement Specialist LLC increased its stake in shares of Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after acquiring an additional 69 shares during the last quarter. Finally, WASHINGTON TRUST Co lifted its holdings in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after acquiring an additional 46 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Cencora

In related news, EVP Silvana Battaglia sold 5,000 shares of the firm's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the transaction, the executive vice president now directly owns 15,374 shares in the company, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the transaction, the chairman now directly owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This represents a 4.38 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,675 shares of company stock valued at $8,034,778 over the last ninety days. Corporate insiders own 10.80% of the company's stock.

Cencora Stock Up 1.9 %

COR traded up $5.31 during trading hours on Friday, reaching $284.46. 1,509,188 shares of the stock traded hands, compared to its average volume of 1,506,610. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The firm's fifty day simple moving average is $260.27 and its two-hundred day simple moving average is $245.01. The company has a market cap of $55.16 billion, a price-to-earnings ratio of 40.46, a PEG ratio of 1.31 and a beta of 0.55. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $296.65.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.77%. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Analysts Set New Price Targets

A number of research firms recently issued reports on COR. Wells Fargo & Company boosted their target price on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a report on Friday, March 14th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Evercore ISI lifted their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. JPMorgan Chase & Co. boosted their price target on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Finally, Bank of America raised their price objective on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $284.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.